On June 4, La Jolla Pharmaceutical Company (NASDAQ:LJPC) a leader in the development of therapeutics targeting significant unmet life-threatening diseases, announced that it has completed enrollment of GCS-100-CS-4003 (“4003 study”), its Phase 2 Extension study of GCS-100 in chronic kidney disease (“CKD”). The 4003 study was initiated to study the long-term safety and efficacy of GCS-100 in patients who completed the initial 12-week Phase 2 study (GCS-100-CS-4002). A total of 93 patients enrolled across 5 sites. Initial data from the 4003 Extension study is expected late this year. La Jolla Pharmaceutical Company (NASDAQ:LJPC) weekly performance is 16.50%. On last trading day company shares ended up $9.11. Analysts mean target price for the company is $34.75. La Jolla Pharmaceutical Company (NASDAQ:LJPC) distance from 50-day simple moving average (SMA50) is -1.21%.
June 2, 2014 — The Norwegian Vaccine Company Vaccibody and Phibro Animal Health Corp (NASDAQ:PAHC) a global animal health and mineral nutrition company, have signed a global exclusive license agreement which grants Phibro and its affiliates the right to develop, market and sell novel vaccines for the poultry market using the Vaccibody platform technology. Under the agreement, Phibro Animal Health Corp (NASDAQ:PAHC) shares advanced 0.86% in last trading session and ended the day on $22.18. Gross Margin is 28.60% and its return on assets is 8.20%.
Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) a pharmaceutical company developing new and more effective therapies to treat cancer, announced that the independent Data and Safety Monitoring Board (DSMB) for the Company’s Phase 3 clinical study of CPX-351 (cytarabine:daunorubicin) Liposome Injection versus the conventional cytarabine and daunorubicin treatment regimen (commonly referred to as 7+3) as first-line therapy in older patients with high-risk (secondary) acute myeloid leukemia (AML) has completed a planned safety review and recommended that the study should continue as planned without any modifications. Celator Pharmaceuticals Inc (NASDAQ:CPXX) shares moved up 5.17% in last trading session and was closed at $2.83, while trading in range of $2.60 – $2.91.
Alder BioPharmaceuticals, Inc., (NASDAQ:ALDR) a clinical-stage biopharmaceutical company developing therapeutic antibodies for the treatment of migraine, autoimmune and inflammatory diseases, announced that members of Alder’s senior management team will present upcoming conference in June: Wells Fargo Securities 2014 Healthcare Conference, Tuesday, June 17, 2014 , 4:40 p.m. EDT at Boston, MA Alder Biopharmaceuticals Inc (NASDAQ:ALDR) ended the last trading day at $17.43. Company weekly volatility is calculated as 10.01% and price to cash ratio as 22.46. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) showed a positive weekly performance of 25.22%.
Albany Molecular Research Inc (NASDAQ:AMRI)‘s stock had its “overweight” rating reiterated by investment analysts at Morgan Stanley in a note issued to investors on Wednesday. They currently have a $21.00 target price on the stock, up from their previous target price of $19.00. Morgan Stanley’s target price indicates a potential upside of 20.41% from the company’s current price. Albany Molecular Research, Inc. (NASDAQ:AMRI) net profit margin is 3.90% and weekly performance is 9.44%. On last trading day company shares ended up $18.67. Analysts mean target price for the company is $16.00. Albany Molecular Research, Inc. (NASDAQ:AMRI) distance from 50-day simple moving average (SMA50) is 14.69%.